IVIG Privigen denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for ivig privigen are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Privigen (IVIG) as Duplicate Therapy

A duplicate-therapy denial means Humana has determined that another covered therapy already on your profile serves the same clinical purpose as Privigen (immune globulin intravenous, human — 10%). This most commonly arises when a patient is prescribed a subcutaneous immunoglobulin product (SCIG) and IVIG simultaneously, or when a different IVIG brand is already authorized. Humana's system flags both as immunoglobulin replacement or modulation and treats the second as duplicative. The denial does not mean IVIG is uncovered — it means the plan believes one product is sufficient.

## Why This Denial Is Appealable

Duplicate-therapy denials are regularly overturned when the prescriber documents a clinical reason that one formulation or route of administration is specifically necessary for the patient. Intravenous and subcutaneous immunoglobulin products differ in pharmacokinetics, infusion-related tolerability, and suitability for specific conditions and patients. If Privigen is prescribed because the patient has a documented adverse reaction to an SCIG product, requires hospital-based infusion for monitoring, or has a condition in which IVIG specifically is the evidence-supported route, those facts belong in the appeal record. Additionally, if Privigen is replacing — rather than supplementing — a previously authorized product that is now discontinued or unavailable, the "duplicate" characterization is factually incorrect.

## Your Federal Appeal Rights

• Internal appeal: ACA §2719 and ERISA §503 require Humana to conduct a full-and-fair internal review. File within the deadline stated on your denial notice.
• External review: After an adverse internal determination, you may request review by an Independent Review Organization. The external-review window is typically around four months from the final adverse determination. Expedited review is available when delay would seriously jeopardize health or the ability to regain maximum function.

## Concrete Appeal Steps and Timeline

1. Request the denial letter and Humana's current medical policy for immunoglobulin therapy — confirm exactly which product it considers duplicative. 2. Audit the active medication list: confirm whether the "duplicate" product is actually being used, and if not, request removal from the active profile. 3. Have the prescribing physician document the clinical distinction: why Privigen specifically (IVIG, IV route, this product) is medically necessary versus the alternative Humana would substitute. 4. Submit the internal appeal with supporting clinical records before the deadline. 5. Standard pre-service internal appeals must be resolved within 30 days; urgent appeals within 72 hours.

## Documentation to Gather

• Denial letter specifying the therapy Humana considers duplicative
• Current medication list confirming actual drug regimen
• Adverse reaction or tolerability records for any alternative product, if applicable
• Diagnosis and clinical records documenting the condition for which Privigen is prescribed
• Prescriber letter of medical necessity explaining clinical rationale for Privigen specifically
• Infusion administration records demonstrating route and monitoring requirements, if relevant

## Criteria-Mapping Structure

Obtain Humana's immunoglobulin medical policy. List each coverage criterion and each duplicate-therapy exclusion condition. For each exclusion, document precisely why it does not apply — or, for each coverage criterion, document the specific chart fact that satisfies it. A point-by-point rebuttal of the duplicate-therapy finding is far more effective than a general narrative appeal.